Table 1.

List of reported cases of pazopanib-induced PRES.

Time Interval between Discontinuation of Pazopanib and Resolution of PRES Symptoms	Time Interval between Initiation of Pazopanib and PRES	Dose	Primary Cancer	Age/Gender	Author
1 day	21 days	Not specified	RCC	40/F	Chelis et al. [4]
6 days	8 weeks	800 mg/day	RCC	63/F	Foerster et al. [22]
2 days	4 weeks	Not specified	RCC	76/M	Asaithambi et al. [23]
Not specified	3 weeks	Not specified	RCC	69/F	Miller-Patterson et al. [24]
60 h	16–20 weeks	400 mg/day	Testicular tumour	32/M	Arslan et al. [25]
3 days	9 days	800 mg/day	RCC	56/F	Miaris et al. [26]
5 days	5–6 weeks	800 mg/day	Retroperitoneal soft tissue sarcoma	49/F	Deguchi et al. [27]
5 days	4 days	800 mg/day	HCC	76/F	Wu et al. [28]
5 days	20 months	Not specified	Hurthel cell thyroid carcinoma	56/F	Koleszar et al. [29]
9 days	4 days	Not specified	Uterine sarcoma	64/F	Takahashi et al. [30]
6 days	12 days	600 mg/day	RCC	73/F	Wong So et al. [31]
7 days	3 days	800 mg/day	Uterine sarcoma	64/F	Tatsumichi et al. [32]

Abbreviation: F, Female; M, Male; PRES, posterior reversible encephalopathy syndrome; RCC, renal cell carcinoma; HCC, hepato-cellular carcinoma.